Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β2-agonists in Patients with Moderate to Severe Asthma: A Randomized, Controlled Study

被引:3
|
作者
Wang, Yan [1 ]
Chen, Ping [2 ]
Dai, Anna [1 ]
Shang, Shengyun [1 ]
Kong, Lingfei [1 ]
机构
[1] China Med Univ, Hosp 1, Inst Resp Dis, 155 Nanjing North St, Shenyang 110001, Liaoning Provin, Peoples R China
[2] Gen Hosp Shenyang Mil Reg, Resp Med, Shenyang, Liaoning, Peoples R China
关键词
fluticasone aerosol; moderate to severe persistent asthma; salmeterol/fluticasone propionate aerosol; theophylline tablets; treatment; PERSISTENT ASTHMA; LUNG-FUNCTION; BUDESONIDE; THERAPY; MONTELUKAST;
D O I
10.1016/j.clinthera.2016.10.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol. Methods: After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/ fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment. The main outcome measurements were forced expiratory volume in 1 second and fractional concentration of exhaled nitric oxide value, whereas the secondary measures were forced vital capacity, peak expiratory flow value, and Asthma Control Test/Asthma Quality of Life Questionnaire score. Findings: Forty-four cases completed the course, with 23 cases in the experiment group and 21 cases in the control group. The forced expiratory volume in 1 second values of both groups were significantly improved from before (P < 0.05). The fractional concentration of exhaled nitric oxide values of both groups were significantly decreased from before (P < 0.05). The secondary outcome measurements after treatment achieved obvious improvement from baseline (P < 0.05) in both. There was no significant difference between the 2 groups in all measurements. In addition, the blood biochemistry results, ECG results, and vital signs of both groups had no significant abnormality. Implications: There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:2622 / 2627
页数:6
相关论文
共 50 条
  • [1] Inhaled corticosteroids plus long-acting β2-agonists as a combined therapy in asthma
    García-Marcos, L
    Schuster, A
    Barroso, NC
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (01) : 23 - 39
  • [2] Inhaled corticosteroids, combined with long-acting β2-agonists, improve the perception of bronchoconstriction in asthma
    Bijl-Hofland, ID
    Cloosterman, SGM
    Folgering, HTM
    van den Elshout, FJJ
    van Weel, C
    van Schayck, CP
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (05) : 764 - 769
  • [3] Long-acting inhaled β2-agonists in asthma therapy
    Moore, RH
    Khan, A
    Dickey, BF
    CHEST, 1998, 113 (04) : 1095 - 1108
  • [4] Long-Acting β2 Agonists and Inhaled Corticosteroids in Asthma
    Lipworth, Brian J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (09) : 853 - 854
  • [5] Nocturnal asthma uncontrolled by inhaled corticosteroids -: Theophylline or long-acting β2 agonists?
    Holimon, TD
    Chafin, CC
    Self, TH
    DRUGS, 2001, 61 (03) : 391 - 418
  • [6] Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists
    Zhang, Shiyuan
    Czira, Alexandrosz
    Harley, Julia
    Rothnie, Kieran J.
    Lee, Lauren
    Small, Mark
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2025, 35 (01)
  • [8] Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
    Sousa-Pinto, B.
    Louis, R.
    Anto, J. M.
    Amaral, R.
    Sa-Sousa, A.
    Czarlewski, W.
    Brussino, L.
    Canonica, G. W.
    Chaves Loureiro, C.
    Cruz, A. A.
    Gemicioglu, B.
    Haahtela, T.
    Kupczyk, M.
    Kvedariene, V.
    Larenas-Linnemann, D. E.
    Okamoto, Y.
    Ollert, M.
    Pfaar, O.
    Pham-Thi, N.
    Puggioni, F.
    Regateiro, F. S.
    Romantowski, J.
    Sastre, J.
    Scichilone, N.
    Taborda-Barata, L.
    Ventura, M. T.
    Agache, I.
    Bedbrook, A.
    Becker, S.
    Bergmann, K. C.
    Bosnic-Anticevich, S.
    Bonini, M.
    Boulet, L. -P.
    Brusselle, G.
    Buhl, R.
    Cecchi, L.
    Charpin, D.
    de Blay, F.
    Del Giacco, S.
    Ivancevich, J. C.
    Jutel, M.
    Klimek, L.
    Kraxner, H.
    Kuna, P.
    Laune, D.
    Makela, M.
    Morais-Almeida, M.
    Nadif, R.
    Niedoszytko, M.
    Papadopoulos, N. G.
    PULMONOLOGY, 2025, 31 (01):
  • [9] Asthma therapy with inhaled corticosteroids and long-acting beta 2-agonists - MART model
    Grzelewska-Rzymowska, Iwona
    Gorski, Pawel
    PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2014, 10 (01): : 15 - 24
  • [10] Management of Chronic Obstructive Pulmonary Disease: Insights into Patient Profile - Use of Inhaled Corticosteroids/Long-Acting β2-Agonists or Long-Acting β2-Agonists/Long-acting Muscarinic Antagonists
    Kishore, Nevin
    Moitra, Saibal
    Sircar, Mrinal
    INDIAN JOURNAL OF RESPIRATORY CARE, 2020, 9 (02) : 162 - 170